Litcius/Paper detail

Ambrisentan in portopulmonary hypertension: A multicenter, open-label trial

Ioana R. Preston, Charles D. Burger, Sonja Bartolome, Zeenat Safdar, Michael J. Krowka, Namita Sood, H. James Ford, Wejdan Battarjee, Murali M. Chakinala, Mardi Gomberg‐Maitland, Nicholas S. Hill

2020The Journal of Heart and Lung Transplantation50 citationsDOI

Topics & Concepts

AmbrisentanPortopulmonary hypertensionMedicineInternal medicinePulmonary wedge pressurePulmonary hypertensionCardiologyVascular resistanceBlood pressureOpen labelCardiac indexHemodynamicsClinical trialPortal hypertensionCardiac outputCirrhosisEndothelin receptorReceptorBosentanPulmonary Hypertension Research and TreatmentsHeart Failure Treatment and ManagementCardiovascular Function and Risk Factors
Ambrisentan in portopulmonary hypertension: A multicenter, open-label trial | Litcius